Drug profile · INN
digoxin
LANOXIN
digoxin (LANOXIN) is a sodium/potassium-transporting atpase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — digoxin
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 2
- Programs
- 11
- Data quality
- 0.84
Quick answer
digoxin (LANOXIN) is a sodium/potassium-transporting atpase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium/potassium-transporting ATPase inhibitor
Primary target: Sodium/potassium-transporting ATPase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is digoxin?
digoxin (LANOXIN) is a sodium/potassium-transporting atpase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for digoxin?
LANOXIN is a marketed brand name for digoxin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of digoxin?
digoxin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.